Zealand Pharma (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions
6/17/2014 9:00:44 AM
Copenhagen, 17 June 2014 – Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) provides a summary of new clinical data and information presented on Lyxumia® (lixisenatide) and on LixiLan, the fixed-ratio combination of Lyxumia® with Lantus®, during the American Diabetes Association’s 74th Scientific Sessions, held in San Francisco, 13 – 17 June 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by